Cyclacel Phar Pr Stock Price, News & Analysis

Cyclacel Pharmaceuticals announced it will report its third quarter 2022 financial results on November 9, 2022. A conference call and live webcast are scheduled for 4:30 PM Eastern Time on the same day. Cyclacel is focused on developing cancer medications based on cell cycle and transcriptional regulation biology, with drug candidates such as fadraciclib and CYC140 undergoing clinical evaluation. The company maintains a commitment to advancing its pipeline for oncology and hematology.

Cyclacel Pharmaceuticals reported promising data from its ongoing Phase 1/2 study of fadraciclib, a CDK2/9 inhibitor, for treating advanced solid tumors and lymphomas. Out of 18 evaluated patients, 2 out of 3 with T-cell lymphoma achieved partial responses, and 11 of 15 with solid tumors maintained stable disease. Notably, no dose-limiting toxicities were observed at dose levels up to 100mg BID. The study is advancing to the sixth dose level of 150mg BID. The company plans to present more data at the upcoming Research & Development Day on October 31, 2022.

Cyclacel Pharmaceuticals announced a research and development day on October 31, 2022, at 10 am ET, focusing on its CDK2/9 inhibitor oral fadraciclib and oral PLK1 inhibitor CYC140. The event will feature presentations from key opinion leaders on unmet medical needs in treating T-cell lymphomas and hepatobiliary cancers. Senior management will provide updates on patient data from the Phase 1/2 study for both drug candidates. A live Q&A will follow the presentations, offering insight into Cyclacel's oncology pipeline.

Cyclacel Pharmaceuticals will present preliminary dose escalation data for fadraciclib, a CDK2/9 inhibitor, at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics from October 26-28, 2022, in Barcelona, Spain. This Phase 1/2 clinical trial focuses on patients with advanced solid tumors and lymphoma. Fadraciclib aims to induce apoptotic cancer cell death and has shown efficacy in prior trials, providing positive outcomes for patients with certain cancer profiles. The presentation details include the study's title, abstract number, and schedule.

Cyclacel Pharmaceuticals announced participation in the Ladenburg Thalmann 2022 Healthcare Conference on September 29, 2022. The event will take place at 9:30 AM ET in Track 2, St Germain III, New York. A fireside chat presentation format will be used. Cyclacel is focused on developing innovative cancer treatments, particularly through its lead candidates, fadraciclib and CYC140, targeting solid tumors and hematological malignancies. For further details, visit cyclacel.com.

Cyclacel Pharmaceuticals reported second quarter 2022 financial results, highlighting the progress of oral fadraciclib, a CDK2 and CDK9 inhibitor. The drug demonstrated good tolerability and early efficacy in solid tumors and lymphomas, with plans to enter Phase 2 proof-of-concept in 2H 2022. Cash and equivalents totaled $29.1 million, expected to fund operations into 2H 2023. R&D expenses were $4.2 million, with a net loss of $4.6 million. A conference call is scheduled for August 10, 2022.

Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) will announce its second quarter 2022 financial results on August 10, 2022. The company focuses on developing innovative cancer medicines, including fadraciclib and CYC140. A conference call will take place at 4:30 p.m. EDT on the same day, which will include a live webcast and archived audio options. Cyclacel acknowledges risks related to its clinical trials and product candidates, as specified in their forward-looking statements.

Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) announced the completion of enrollment in its Phase 1 dose escalation study of oral fadraciclib in solid tumors. No dose limiting toxicities were reported, and evidence shows target engagement for CDK2 and CDK9. Early anticancer activity was noted, with patients experiencing partial responses and stable disease across various cancers, including endometrial and pancreatic cancers. The company plans an R&D Day in fall 2022 to share more data.

Cyclacel Pharmaceuticals (NASDAQ: CYCC, CYCCP) announced the election of Kenneth M. Ferguson, Ph.D., to its Board of Directors, representing 6% Convertible Exchangeable Preferred stockholders. Dr. Ferguson brings over 30 years of drug development experience, previously serving as Chief Scientific Officer at EMulate Therapeutics and Chief Development Officer at Omeros Corp. He is expected to provide valuable insights for Cyclacel’s clinical development programs, particularly for its promising cancer therapies, fadraciclib and CYC140, currently in Phase 1/2 clinical studies.